News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CLOUDBREAK-B (02592.HK) CBT-199 Clinical Study Approved to Proceed
CLOUDBREAK-B (02592.HK) announced that the US Food and Drug Administration has completed its safety review of the Investigational New Drug application for its ophthalmic drug CBT-1...
Reset
Send
The window will close in 5 seconds
CLOUDBREAK-B (02592.HK) CBT-199 Clinical Study Approved to Proceed
Close
Recommend
2
Positive
0
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

CLOUDBREAK-B (02592.HK)  -0.050 (-3.759%)   announced that the US Food and Drug Administration has completed its safety review of the Investigational New Drug application for its ophthalmic drug CBT-199, concluding that the company may proceed with the proposed clinical study. (ss/a)(HK stocks quote is delayed for at least 15 mins.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.